BerandaABVX • NASDAQ
add
Abivax SA
$125,80
Sebelum Jam Perdagangan Normal:(1,09%)+1,37
$127,17
Tutup: 15 Apr, 07.00.00 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$121,31
Rentang hari
$121,03 - $127,44
Rentang tahun
$5,59 - $148,83
Kapitalisasi pasar
8,60Â M EUR
Volume Rata-Rata
1,04Â jt
Rasio P/E
-
Hasil dividen
-
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (EUR) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 1,91Â jt | -55,37% |
Biaya operasional | 73,56Â jt | 50,47% |
Penghasilan bersih | -81,96Â jt | -108,14% |
Margin laba bersih | -4,28Â rb | -366,40% |
Penghasilan per saham | — | — |
EBITDA | -70,76Â jt | -61,81% |
Tarif pajak efektif | -7,68% | — |
Neraca
Total aset
Total liabilitas
| (EUR) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 530,38Â jt | 267,41% |
Total aset | 584,34Â jt | 184,73% |
Total liabilitas | 129,14Â jt | -21,57% |
Total ekuitas | 455,20 jt | — |
Saham yang beredar | 79,19 jt | — |
Harga terhadap nilai buku | 20,92 | — |
Tingkat pengembalian aset | -28,97% | — |
Tingkat pengembalian modal | -33,40% | — |
Arus Kas
Perubahan kas bersih
| (EUR) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -81,96Â jt | -108,14% |
Kas dari operasi | -23,23Â jt | 30,69% |
Kas dari investasi | -12,74Â jt | -2.391,73% |
Kas dari pembiayaan | -39,55Â jt | -578,85% |
Perubahan kas bersih | -73,02Â jt | -101,54% |
Arus kas bebas | -20,15 jt | — |
Tentang
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Didirikan
4 Des 2013
Situs
Karyawan
69
